Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Liabilities and Shareholders Equity (2023 - 2026)

BioAge Labs' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $294.9 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 17.68% to $294.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 81.99% increase, with the full-year FY2025 number at $294.9 million, down 17.68% from a year prior.
  • Liabilities and Shareholders Equity hit $294.9 million in Q4 2025 for BioAge Labs, down from $305.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BIOA hit a ceiling of $358.2 million in Q4 2024 and a floor of $25.9 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $283.9 million across 3 years, with a median of $322.1 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 1281.86% in 2024 and later fell 17.68% in 2025.
  • Tracing BIOA's Liabilities and Shareholders Equity over 3 years: stood at $25.9 million in 2023, then soared by 1281.86% to $358.2 million in 2024, then dropped by 17.68% to $294.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BIOA at $294.9 million in Q4 2025, $305.1 million in Q3 2025, and $322.1 million in Q2 2025.